Sol-Gel Technologies Shares Outstanding 2016-2026 | SLGL
Sol-Gel Technologies shares outstanding from 2016 to 2026. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
|
Sol-Gel Technologies Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
|
Sol-Gel Technologies Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2026-03-31 | 3 |
| 2025-12-31 | 3 |
| 2025-09-30 | 3 |
| 2025-06-30 | 3 |
| 2025-03-31 | 3 |
| 2024-12-31 | 3 |
| 2024-09-30 | 3 |
| 2024-06-30 | 3 |
| 2024-03-31 | 3 |
| 2023-12-31 | 3 |
| 2023-09-30 | 3 |
| 2023-06-30 | 3 |
| 2023-03-31 | 2 |
| 2022-12-31 | 2 |
| 2022-09-30 | 2 |
| 2022-06-30 | 2 |
| 2022-03-31 | 2 |
| 2021-12-31 | 2 |
| 2021-09-30 | 2 |
| 2021-06-30 | 2 |
| 2021-03-31 | 2 |
| 2020-12-31 | 2 |
| 2020-09-30 | 2 |
| 2020-06-30 | 2 |
| 2020-03-31 | 2 |
| 2019-12-31 | 2 |
| 2019-09-30 | 2 |
| 2019-06-30 | 2 |
| 2019-03-31 | 2 |
| 2018-12-31 | 2 |
| 2018-09-30 | 2 |
| 2018-06-30 | 2 |
| 2018-03-31 | 1 |
| 2017-12-31 | |
| 2017-09-30 | |
| 2017-06-30 | 1 |
| 2016-12-31 | |
| 2015-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.210B | $0.019B |
| Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |